An experimental therapy for a rare blood cancer was rejected by the FDA though internal reviewers had recommended it be cleared ...

Eli Lilly's experimental weight-loss pill, orforglipron, caused more side effects and treatment discontinuations than Novo ...

Popular weight-loss drugs, including Ozempic, Wegovy, Trulicity and Mounjaro, produced by independent pharmacy labs, sickened ...

Eli Lilly (LLY) has built up its inventory for its experimental weight loss pill, orforglipron, as the Indiana-based pharma giant awaits a potential FDA approval for the oral GLP-1 drug over the ...

Eli Lilly and Company (NYSE: LLY) has stockpiled $1.5 billion worth of inventory of its experimental oral weight-loss drug, orforglipron, according to a regulatory filing on Thursday. This significant ...

A bottle of Wegovy tablets its box and an Ozempic pen in the background. For decades, researchers have been looking for an effective weight-loss pill. But the recent success of glucagon-like peptide-1 ...

AstraZeneca will push the pill, elecoglipron, into a comprehensive late-stage program that will test the drug as a monotherapy, as part of a combination regimen and for several indications.

Novo Nordisk said it filed a federal lawsuit Feb. 9 against telehealth provider Hims & Hers, alleging the company infringed on Novo's patent by selling versions of its blockbuster weight-loss drug ...

Hims & Hers caused a firestorm last week when it revealed that it planned to launch a knockoff version of Novo Nordisk's new oral weight loss medicine. But the reaction to the move has caused the ...

Novo Nordisk, maker of Wegovy, saw its stock rise 6.5% after the opening bell on Monday. The company and the U.S. Food and Drug Administration threatened legal action against Hims & Hers, over its ...